Eli Lilly and Company has reassumed the worldwide development and commercialization rights for novel basal insulin analog giving a scope to diabetes alliance signed with Boehringer concerning LY2605541.
Lilly also considers initiating remaining pre-planned trials to assess the safety, efficacy and differentiation of LY2605541 in 2013 and 2014 while five IMAGINE clinical trials are being conducted at present.
If the studies yield positive results, the company expects to submit the basal insulin analog to regulatory authorities in 2014.
Lilly Diabetes president Enrique Conterno said the company has a deeper history with patients impacted by diabetes than any other group.
"If approved, this basal insulin analog will be an important addition to the Lilly portfolio as we work to provide a broad portfolio of diabetes medicines to our customers," Conterno added.
Lilly and Boehringer Ingelheim will continue working together to jointly develop and commercialize the other compounds in the diabetes alliance formed between them in January 2011.
Citing independent strategic portfolio considerations Boehringer has chosen to terminate the partnership with Lilly regarding LY2605541.
